Impact of fear of cancer recurrence on survival among lymphoma patients
Objective This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL). Methods In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent betw...
Gespeichert in:
Veröffentlicht in: | Psycho-oncology (Chichester, England) England), 2020-02, Vol.29 (2), p.364-372 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 372 |
---|---|
container_issue | 2 |
container_start_page | 364 |
container_title | Psycho-oncology (Chichester, England) |
container_volume | 29 |
creator | Kim, Seok Jin Kang, Danbee Kim, Im Ryung Yoon, Sang Eun Kim, Won Seog Butow, Phyllis N. Guallar, Eliseo Cho, Juhee |
description | Objective
This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL).
Methods
In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ‐C30. Participants were actively followed up for all‐cause and disease‐specific mortality.
Results
In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all‐cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15‐5.54), and the association was stronger in indolent non‐Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04‐43.92). Participants with severe FCR were also at higher risk of lymphoma‐specific mortality (HR = 2.62; 95% CI = 1.13‐6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR.
Conclusions
A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings. |
doi_str_mv | 10.1002/pon.5265 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2309482693</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2309482693</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3495-8efdb2c58bc31cf404670130976d256fe1edf3873570591eab490099e2a539193</originalsourceid><addsrcrecordid>eNp1kE9LwzAYh4Mobk7BTyABL14686dJm6OIzsFwHvRc0vStdrRNTdbJvr2pmwqCp_c9PDz8eBA6p2RKCWHXnW2ngklxgMaUKBVRSenh8IskUixWI3Ti_YqQACt5jEacShELHo_RbN502qyxLXEJ2g3X6NaAww5M7xyEH9sW-95tqo2usW5s-4rrbdO92UbjTq8raNf-FB2VuvZwtr8T9HJ_93z7EC2Ws_ntzSIyPFYiSqEscmZEmhtOTRmTWCaEcqISWTAhS6BQlDxNuEiIUBR0HquwWQHTgiuq-ARd7byds-89-HXWVN5AXesWbO8zFlxxyqTiAb38g65s79qwLlAiZEuloL9C46z3Dsqsc1Wj3TajJBviZiFuNsQN6MVe2OcNFD_gd80ARDvgo6ph-68oe1o-fgk_AaRogPg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2350028651</pqid></control><display><type>article</type><title>Impact of fear of cancer recurrence on survival among lymphoma patients</title><source>Wiley Journals</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Kim, Seok Jin ; Kang, Danbee ; Kim, Im Ryung ; Yoon, Sang Eun ; Kim, Won Seog ; Butow, Phyllis N. ; Guallar, Eliseo ; Cho, Juhee</creator><creatorcontrib>Kim, Seok Jin ; Kang, Danbee ; Kim, Im Ryung ; Yoon, Sang Eun ; Kim, Won Seog ; Butow, Phyllis N. ; Guallar, Eliseo ; Cho, Juhee</creatorcontrib><description>Objective
This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL).
Methods
In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ‐C30. Participants were actively followed up for all‐cause and disease‐specific mortality.
Results
In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all‐cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15‐5.54), and the association was stronger in indolent non‐Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04‐43.92). Participants with severe FCR were also at higher risk of lymphoma‐specific mortality (HR = 2.62; 95% CI = 1.13‐6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR.
Conclusions
A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.</description><identifier>ISSN: 1057-9249</identifier><identifier>EISSN: 1099-1611</identifier><identifier>DOI: 10.1002/pon.5265</identifier><identifier>PMID: 31654534</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Cancer ; Clinical outcomes ; Cohort analysis ; Fear & phobias ; fear of cancer recurrence ; Functional status ; Health risk assessment ; Health status ; Lymphoma ; Mortality ; Quality of life ; Questionnaires ; Recurrence ; Severity ; Social functioning ; survival</subject><ispartof>Psycho-oncology (Chichester, England), 2020-02, Vol.29 (2), p.364-372</ispartof><rights>2019 John Wiley & Sons, Ltd.</rights><rights>2020 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3495-8efdb2c58bc31cf404670130976d256fe1edf3873570591eab490099e2a539193</citedby><cites>FETCH-LOGICAL-c3495-8efdb2c58bc31cf404670130976d256fe1edf3873570591eab490099e2a539193</cites><orcidid>0000-0003-3562-6954 ; 0000-0001-9081-0266</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpon.5265$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpon.5265$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,30999,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31654534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kang, Danbee</creatorcontrib><creatorcontrib>Kim, Im Ryung</creatorcontrib><creatorcontrib>Yoon, Sang Eun</creatorcontrib><creatorcontrib>Kim, Won Seog</creatorcontrib><creatorcontrib>Butow, Phyllis N.</creatorcontrib><creatorcontrib>Guallar, Eliseo</creatorcontrib><creatorcontrib>Cho, Juhee</creatorcontrib><title>Impact of fear of cancer recurrence on survival among lymphoma patients</title><title>Psycho-oncology (Chichester, England)</title><addtitle>Psychooncology</addtitle><description>Objective
This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL).
Methods
In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ‐C30. Participants were actively followed up for all‐cause and disease‐specific mortality.
Results
In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all‐cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15‐5.54), and the association was stronger in indolent non‐Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04‐43.92). Participants with severe FCR were also at higher risk of lymphoma‐specific mortality (HR = 2.62; 95% CI = 1.13‐6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR.
Conclusions
A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.</description><subject>Cancer</subject><subject>Clinical outcomes</subject><subject>Cohort analysis</subject><subject>Fear & phobias</subject><subject>fear of cancer recurrence</subject><subject>Functional status</subject><subject>Health risk assessment</subject><subject>Health status</subject><subject>Lymphoma</subject><subject>Mortality</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Recurrence</subject><subject>Severity</subject><subject>Social functioning</subject><subject>survival</subject><issn>1057-9249</issn><issn>1099-1611</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp1kE9LwzAYh4Mobk7BTyABL14686dJm6OIzsFwHvRc0vStdrRNTdbJvr2pmwqCp_c9PDz8eBA6p2RKCWHXnW2ngklxgMaUKBVRSenh8IskUixWI3Ti_YqQACt5jEacShELHo_RbN502qyxLXEJ2g3X6NaAww5M7xyEH9sW-95tqo2usW5s-4rrbdO92UbjTq8raNf-FB2VuvZwtr8T9HJ_93z7EC2Ws_ntzSIyPFYiSqEscmZEmhtOTRmTWCaEcqISWTAhS6BQlDxNuEiIUBR0HquwWQHTgiuq-ARd7byds-89-HXWVN5AXesWbO8zFlxxyqTiAb38g65s79qwLlAiZEuloL9C46z3Dsqsc1Wj3TajJBviZiFuNsQN6MVe2OcNFD_gd80ARDvgo6ph-68oe1o-fgk_AaRogPg</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Kim, Seok Jin</creator><creator>Kang, Danbee</creator><creator>Kim, Im Ryung</creator><creator>Yoon, Sang Eun</creator><creator>Kim, Won Seog</creator><creator>Butow, Phyllis N.</creator><creator>Guallar, Eliseo</creator><creator>Cho, Juhee</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3562-6954</orcidid><orcidid>https://orcid.org/0000-0001-9081-0266</orcidid></search><sort><creationdate>202002</creationdate><title>Impact of fear of cancer recurrence on survival among lymphoma patients</title><author>Kim, Seok Jin ; Kang, Danbee ; Kim, Im Ryung ; Yoon, Sang Eun ; Kim, Won Seog ; Butow, Phyllis N. ; Guallar, Eliseo ; Cho, Juhee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3495-8efdb2c58bc31cf404670130976d256fe1edf3873570591eab490099e2a539193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Clinical outcomes</topic><topic>Cohort analysis</topic><topic>Fear & phobias</topic><topic>fear of cancer recurrence</topic><topic>Functional status</topic><topic>Health risk assessment</topic><topic>Health status</topic><topic>Lymphoma</topic><topic>Mortality</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Recurrence</topic><topic>Severity</topic><topic>Social functioning</topic><topic>survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kang, Danbee</creatorcontrib><creatorcontrib>Kim, Im Ryung</creatorcontrib><creatorcontrib>Yoon, Sang Eun</creatorcontrib><creatorcontrib>Kim, Won Seog</creatorcontrib><creatorcontrib>Butow, Phyllis N.</creatorcontrib><creatorcontrib>Guallar, Eliseo</creatorcontrib><creatorcontrib>Cho, Juhee</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Psycho-oncology (Chichester, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Seok Jin</au><au>Kang, Danbee</au><au>Kim, Im Ryung</au><au>Yoon, Sang Eun</au><au>Kim, Won Seog</au><au>Butow, Phyllis N.</au><au>Guallar, Eliseo</au><au>Cho, Juhee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of fear of cancer recurrence on survival among lymphoma patients</atitle><jtitle>Psycho-oncology (Chichester, England)</jtitle><addtitle>Psychooncology</addtitle><date>2020-02</date><risdate>2020</risdate><volume>29</volume><issue>2</issue><spage>364</spage><epage>372</epage><pages>364-372</pages><issn>1057-9249</issn><eissn>1099-1611</eissn><abstract>Objective
This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL).
Methods
In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ‐C30. Participants were actively followed up for all‐cause and disease‐specific mortality.
Results
In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all‐cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15‐5.54), and the association was stronger in indolent non‐Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04‐43.92). Participants with severe FCR were also at higher risk of lymphoma‐specific mortality (HR = 2.62; 95% CI = 1.13‐6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR.
Conclusions
A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31654534</pmid><doi>10.1002/pon.5265</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3562-6954</orcidid><orcidid>https://orcid.org/0000-0001-9081-0266</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1057-9249 |
ispartof | Psycho-oncology (Chichester, England), 2020-02, Vol.29 (2), p.364-372 |
issn | 1057-9249 1099-1611 |
language | eng |
recordid | cdi_proquest_miscellaneous_2309482693 |
source | Wiley Journals; Applied Social Sciences Index & Abstracts (ASSIA) |
subjects | Cancer Clinical outcomes Cohort analysis Fear & phobias fear of cancer recurrence Functional status Health risk assessment Health status Lymphoma Mortality Quality of life Questionnaires Recurrence Severity Social functioning survival |
title | Impact of fear of cancer recurrence on survival among lymphoma patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A08%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20fear%20of%20cancer%20recurrence%20on%20survival%20among%20lymphoma%20patients&rft.jtitle=Psycho-oncology%20(Chichester,%20England)&rft.au=Kim,%20Seok%20Jin&rft.date=2020-02&rft.volume=29&rft.issue=2&rft.spage=364&rft.epage=372&rft.pages=364-372&rft.issn=1057-9249&rft.eissn=1099-1611&rft_id=info:doi/10.1002/pon.5265&rft_dat=%3Cproquest_cross%3E2309482693%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2350028651&rft_id=info:pmid/31654534&rfr_iscdi=true |